Radionuclides in the Management of Leptomeningeal Metastasis: Framework and Opportunities

Franklin C.L. Wong

doi:10.1007/978-3-031-14291-8_12

Radionuclides in the Management of Leptomeningeal Metastasis: Framework and Opportunities

Franklin C.L. Wong

Nuclear Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter surveys the framework under which radiopharmaceuticals are used for the assessment of CSF flow and therapy of leptomeningeal metastasis (LM). The scientific basis is reviewed for development of radiopharmaceuticals for use in LM. The opportunities and limitations in choices of radiopharmaceuticals, imaging, and dosimetry schemes are discussed. Potential novel radiopharmaceuticals and novel use of existing radiopharmaceuticals are examined for future design of radiopharmaceutical trials in LM.

Original language	English (US)
Title of host publication	Radiopharmaceuticals in the Management of Leptomeningeal Metastasis
Publisher	Springer International Publishing
Pages	215-226
Number of pages	12
ISBN (Electronic)	9783031142918
ISBN (Print)	9783031142901
DOIs	https://doi.org/10.1007/978-3-031-14291-8_12
State	Published - Jan 1 2022

Keywords

Clearance time
Geographic targeting
Image-based dosimetry
Jurisdictions
Molecular targeting
Radiation dosimetry
Radiopharmaceuticals
Residence time
Simulation

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-031-14291-8_12

Cite this

@inbook{1318cc6e47fe4e499371754ecfea4afd,

title = "Radionuclides in the Management of Leptomeningeal Metastasis: Framework and Opportunities",

abstract = "This chapter surveys the framework under which radiopharmaceuticals are used for the assessment of CSF flow and therapy of leptomeningeal metastasis (LM). The scientific basis is reviewed for development of radiopharmaceuticals for use in LM. The opportunities and limitations in choices of radiopharmaceuticals, imaging, and dosimetry schemes are discussed. Potential novel radiopharmaceuticals and novel use of existing radiopharmaceuticals are examined for future design of radiopharmaceutical trials in LM.",

keywords = "Clearance time, Geographic targeting, Image-based dosimetry, Jurisdictions, Molecular targeting, Radiation dosimetry, Radiopharmaceuticals, Residence time, Simulation",

author = "Wong, {Franklin C.L.}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-14291-8_12",

language = "English (US)",

isbn = "9783031142901",

pages = "215--226",

booktitle = "Radiopharmaceuticals in the Management of Leptomeningeal Metastasis",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Radionuclides in the Management of Leptomeningeal Metastasis

T2 - Framework and Opportunities

AU - Wong, Franklin C.L.

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2022.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - This chapter surveys the framework under which radiopharmaceuticals are used for the assessment of CSF flow and therapy of leptomeningeal metastasis (LM). The scientific basis is reviewed for development of radiopharmaceuticals for use in LM. The opportunities and limitations in choices of radiopharmaceuticals, imaging, and dosimetry schemes are discussed. Potential novel radiopharmaceuticals and novel use of existing radiopharmaceuticals are examined for future design of radiopharmaceutical trials in LM.

AB - This chapter surveys the framework under which radiopharmaceuticals are used for the assessment of CSF flow and therapy of leptomeningeal metastasis (LM). The scientific basis is reviewed for development of radiopharmaceuticals for use in LM. The opportunities and limitations in choices of radiopharmaceuticals, imaging, and dosimetry schemes are discussed. Potential novel radiopharmaceuticals and novel use of existing radiopharmaceuticals are examined for future design of radiopharmaceutical trials in LM.

KW - Clearance time

KW - Geographic targeting

KW - Image-based dosimetry

KW - Jurisdictions

KW - Molecular targeting

KW - Radiation dosimetry

KW - Radiopharmaceuticals

KW - Residence time

KW - Simulation

UR - http://www.scopus.com/inward/record.url?scp=85160139645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85160139645&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-14291-8_12

DO - 10.1007/978-3-031-14291-8_12

M3 - Chapter

AN - SCOPUS:85160139645

SN - 9783031142901

SP - 215

EP - 226

BT - Radiopharmaceuticals in the Management of Leptomeningeal Metastasis

PB - Springer International Publishing

ER -

Radionuclides in the Management of Leptomeningeal Metastasis: Framework and Opportunities

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this